Centessa Pharmaceuticals (LSE:0ACX) - Stock Price, News & Analysis

0ACX Stock Overview

A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.

0ACX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Centessa Pharmaceuticals plc Competitors

Avacta Group

AIM:AVCT

UK£269.3m

Genus

LSE:GNS

UK£1.2b

Oxford Biomedica

LSE:OXB

UK£369.2m

PureTech Health

LSE:PRTC

UK£396.8m

Price History & Performance

Summary of all time highs, changes and price drops for Centessa Pharmaceuticals
Historical stock prices
Current Share Price	US$11.87
52 Week High	US$13.32
52 Week Low	US$8.49
Beta	1.41
11 Month Change	26.01%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	27.22%

Recent updates

Shareholder Returns

	0ACX	GB Biotechs	GB Market
7D	-10.9%	1.3%	0.2%
1Y	n/a	-18.7%	11.2%

Return vs Industry: Insufficient data to determine how 0ACX performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0ACX performed against the UK Market.

Price Volatility

Is 0ACX's price volatile compared to industry and market?
0ACX volatility
0ACX Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.0%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.6%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0ACX's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0ACX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	77	Saurabh Saha	www.centessa.com

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.

Centessa Pharmaceuticals plc Fundamentals Summary

How do Centessa Pharmaceuticals's earnings and revenue compare to its market cap?
0ACX fundamental statistics
Market cap	US$1.38b
Earnings (TTM)	-US$157.35m
Revenue (TTM)	US$6.85m

201.9x

P/S Ratio

-8.8x

P/E Ratio

Is 0ACX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0ACX income statement (TTM)
Revenue	US$6.85m
Cost of Revenue	US$0
Gross Profit	US$6.85m
Other Expenses	US$164.20m
Earnings	-US$157.35m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.39
Gross Margin	100.00%
Net Profit Margin	-2,296.03%
Debt/Equity Ratio	26.7%

How did 0ACX perform over the long term?

See historical performance and comparison

Centessa Pharmaceuticals LSE:0ACX Stock Report